ABBV
vs
S&P 500
Over the past 12 months, ABBV has underperformed S&P 500, delivering a return of 12% compared to the S&P 500's 24% growth.
Stocks Performance
ABBV vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
||
US |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Performance Gap
ABBV vs S&P 500
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
||
US |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Performance By Year
ABBV vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
||
US |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Competitors Performance
Abbvie Inc vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
LU |
Tenaris SA
MIL:TEN
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
Abbvie Inc
Glance View
AbbVie Inc., a leader in the pharmaceutical industry, emerged from its parent company Abbott Laboratories in 2013, with a mission centered around addressing some of the world’s most complex and serious diseases. At its core, AbbVie is a research-driven entity that leverages scientific innovation to develop advanced therapies. With a robust pipeline, the company focuses on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and women's health. It has developed a diversified portfolio designed to tackle challenging health issues. The company devotes significant resources to research and development, fostering a culture that celebrates scientific discovery as a pathway to improving patient lives worldwide. Revenue generation for AbbVie is deeply intertwined with its treatment offerings, particularly its lineup of blockbuster drugs. The flagship product, Humira, an anti-inflammatory medication, has consistently stood as one of the top-selling drugs globally. Despite facing patent expirations for Humira, AbbVie has strategically navigated this challenge through its robust product pipeline, which includes promising medicines like Skyrizi and Rinvoq in immunology. The company also expanded its revenue potential significantly with the acquisition of Allergan in 2020, adding Botox and other products in aesthetics and eye care to its portfolio. The calculated diversification of revenue streams ensures AbbVie maintains a competitive edge, securing its position as a formidable player in the pharmaceutical industry.